BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10935058)

  • 1. Promising results for tenofovir.
    AIDS Patient Care STDS; 2000 Jul; 14(7):396. PubMed ID: 10935058
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir DF trial announced by Gilead.
    Eagan L
    Posit Living; 2000 Jul; 9(6):22, 54. PubMed ID: 12492018
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
    [No Abstract]   [Full Text] [Related]  

  • 4. Tenofovir DF on the horizon. Investigational nucleotide reverse transcriptor inhibitor could be on pharmacy shelves soon.
    Eagan L
    Posit Living; 2001; 10(5):21. PubMed ID: 11693102
    [No Abstract]   [Full Text] [Related]  

  • 5. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of tenofovir.
    AIDS Patient Care STDS; 2002 Jan; 16(1):52. PubMed ID: 11892609
    [No Abstract]   [Full Text] [Related]  

  • 7. Tenofovir--long term results from first-line therapy.
    TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
    [No Abstract]   [Full Text] [Related]  

  • 8. More uses for tenofovir?
    AIDS Treat News; 2001 Jan; (377):4. PubMed ID: 11862808
    [No Abstract]   [Full Text] [Related]  

  • 9. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 10. Tenofovir: FDA hearing on important new antiretroviral.
    James JS
    AIDS Treat News; 2001 Oct; (372):2-4. PubMed ID: 11702411
    [No Abstract]   [Full Text] [Related]  

  • 11. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 13. The potential place of tenofovir in antiretroviral treatment regimens.
    Gazzard BG
    Int J Clin Pract; 2001 Dec; 55(10):704-9. PubMed ID: 11777298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir approved: broad indication.
    James JS
    AIDS Treat News; 2001 Oct; (373):2-3. PubMed ID: 11768879
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir (Viread(R)) access for poor countries.
    James JS
    AIDS Treat News; 2002 Dec; (386):6-7. PubMed ID: 12569875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B infection in an HIV-positive man treated with tenofovir: a case of re-infection or reactivation?
    Richardson D; Lamba H
    Int J STD AIDS; 2004 Mar; 15(3):204-5. PubMed ID: 15038871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cambodia stops important tenofovir prevention trial.
    James JS
    AIDS Treat News; 2004 Jul; (403):4-5. PubMed ID: 15386853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tenofovir (Viread)].
    Sidahora; 2002; (1):20-1. PubMed ID: 12772661
    [No Abstract]   [Full Text] [Related]  

  • 19. [Further indications for tenofovir].
    Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207
    [No Abstract]   [Full Text] [Related]  

  • 20. Gilead sciences releases Viread.
    Giles C
    Surviv News (Atlanta Ga); 2002 Jan; ():15. PubMed ID: 11870987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.